Similar articles

• Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients.

  Rutschmann OT, Zwahlen A. Rutschmann OT, et al. Eur J Clin Microbiol Infect Dis. 1995 May;14(5):441-4. doi: 10.1007/BF02114901. Eur J Clin Microbiol Infect Dis. 1995. PMID: 7556234 Clinical Trial.
• Patient compliance and efficacy of low-dose, long-term prophylaxis in patients with recurrent urinary tract infection.

  Westenfelder M, Vahlensieck W, Reinhartz U. Westenfelder M, et al. Chemioterapia. 1987 Jun;6(2 Suppl):530-2. Chemioterapia. 1987. PMID: 3509492 No abstract available.
• Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.

  Auquer F, Cordón F, Gorina E, Caballero JC, Adalid C, Batlle J; Urinary Tract Infection Study Group. Auquer F, et al. Clin Microbiol Infect. 2002 Jan;8(1):50-4. Clin Microbiol Infect. 2002. PMID: 11906502 Clinical Trial.
• [Norfloxacin--its current role in pharmacotherapy].

  Stojiljković MP, Jovanović D. Stojiljković MP, et al. Vojnosanit Pregl. 1998 May-Jun;55(3):291-304. Vojnosanit Pregl. 1998. PMID: 9720445 Review. Serbian. No abstract available.
• Review of norfloxacin in complicated and recurrent urinary tract infections.

  Schaeffer AJ. Schaeffer AJ. Eur Urol. 1990;17 Suppl 1:19-23. Eur Urol. 1990. PMID: 2191865 Review.